Novo Nordisk Plans International Wegovy Launch After 2M US Prescriptions
Novo Nordisk expects to begin international launches of its oral Wegovy obesity pill later this year pending regulatory approvals, aiming to build on over two million U.S. prescriptions that propelled first-quarter sales above forecasts. AstraZeneca’s FDA approval of Baxfendy for hypertension adds new competition in the cardiovascular and metabolic market.
1. Wegovy Global Expansion
Novo Nordisk has prepared to launch its oral Wegovy obesity pill internationally later this year pending approvals in major markets such as the UK, Germany, and Denmark. The company recorded over two million U.S. prescriptions since January, driving first-quarter sales above expectations and seeking to offset U.S. price reductions and generic challenges in key markets.
2. Rising Competition from Baxfendy
AstraZeneca secured FDA approval for its hypertension treatment Baxfendy, acquired via CinCor Pharma for up to $1.8 billion, targeting patients uncontrolled on existing therapies and aiming for more than $5 billion in annual sales. This new entrant intensifies competition in the cardiovascular and metabolic space where Wegovy operates, potentially influencing market dynamics and pricing strategies.